46 articles about Agena Biosciences
Agena Bioscience® and Manchester University Announce Partnership to Provide Educational Resources to the Pharmacogenomics Industry
Agena Bioscience®, a global provider of genetic testing solutions, announced a partnership with Manchester University to expand awareness and access to PGx educational resources.
Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that it has completed the previously announced acquisition of Agena Biosciences, Inc.
Mesa Laboratories, Inc., a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, announced that it has entered into a definitive agreement to acquire Agena Bioscience, Inc. for a cash purchase price of $300 million, subject to customary purchase price adjustments.
Agena Bioscience®, the global manufacturer of the MassARRAY® System for targeted genetic analysis, announced an exclusive distribution agreement with Alliance Global, the AGBL Group of companies, to bring the MassARRAY technology to many emerging markets across the Middle East, Africa, and Central Asia.
Agena Bioscience Launches New Panel for Detection and Discrimination of SARS-CoV-2 Variants of Concern
Agena Bioscience®, a global provider of low-cost, high-throughput molecular testing solutions, announced the launch of the MassARRAY® SARS-CoV-2 Variant Panel for the detection of key SARS-CoV-2 virus strains, including the UK, South Africa, Brazil and Denmark variants.
Agena Bioscience®, a global provider of low-cost and high-throughput molecular testing solutions, announced that its MassARRAY® SARS-CoV-2 Panel for qualitative detection of the SARS-CoV-2 coronavirus has been granted Emergency Use Authorization from the U.S. Food and Drug Administration.
Agena Bioscience, a global provider of low cost and high-throughput molecular testing solutions, announced the launch of the iPLEX® Pro SARS-CoV-2 Panel for qualitative detection of the novel coronavirus that causes COVID-19.
Agena Improves PGx Testing Accuracy with Launch of VeriDose™ CYP2D6 CNV Panel to Detect Hybrid Alleles
The RUO panel quantifies CYP2D6 copy number, even in the presence of CYP2D6/CYP2D7 hybrid alleles which cannot be detected by commonly used PGx technologies.
Agena Bioscience, a global provider of molecular testing solutions, today announced the release of the Chimeric ID Panel designed to reduce the time and cost of performing chimerism analysis for bone marrow engraftment monitoring studies.
Agena And DaRui Biotechnology Announce China FDA Clearance Of MassARRAY Technology For Diagnostic Use In China
Commercially branded in China as DR MassARRAY by DaRui, the approval of the MALDI-TOF based system for targeted genetic analysis is the successful culmination of the commercial partnership that was initiated in 2016 between the two companies.
Combining LabChip® GX Touch Nucleic Acid Analyzer and MassARRAY® for Optimized Liquid Biopsy Workflow
Agena Bioscience announced today that it has been selected for participation in the CANCER-ID Consortium.
Agena Announces MassARRAY Commercial Partnership Agreement With Dian For China Clinical Laboratory Market
Agena Bioscience announced that it has entered into a commercial partnership agreement with Zhejiang Dian Diagnostics Co., Ltd.
Agena Biosciences today announced it has been selected to participate as an innovative technology provider in the LIMA project.
Agena Biosciences Release: Highly Sensitive Assessment Of Common Somatic Mutations In Pulmonary Non-Small Cell Carcinoma With The MassARRAY System
Agena Biosciences Announces Molecular Health As The First Interpretation Software Provider For MassARRAY Insights
Agena Biosciences Release: MassARRAY System Selected For Illinois State Cystic Fibrosis Screening Of Newborns